MediciNova is a biopharmaceutical company that is developing
novel therapeutics with a primary focus on neurology, respiratory,
and liver diseases with unmet medical needs.
MediciNova is a biopharmaceutical company that is developing
novel therapeutics with a primary focus on neurology, respiratory,
and liver diseases with unmet medical needs.
Press release
|
2025/09/22 MN-166ALSclinical trials MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)  |
|
2025/09/16 MN-166ALSacademic conference MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND |
|
2025/09/03 MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
|
2025/08/26 MN-166ALSclinical trials MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial |
|
2025/07/31 MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million |
|
2025/07/24 MN-166ALSclinical trials MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials |
|
2025/04/14 MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 |
|
2025/04/08 MN-166ALSclinical trials First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients |
|
2025/09/22 MN-166ALSclinical trials MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast) |
|
2025/09/16 MN-166ALSacademic conference MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND |
|
2025/09/03 MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
|
2025/08/26 MN-166ALSclinical trials MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial |
|
2025/07/31 MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million |
|
2025/07/24 MN-166ALSclinical trials MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials |
|
2025/04/14 MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 |
|
2025/04/08 MN-166ALSclinical trials First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients |